Skip to main content
QURE
NASDAQ Life Sciences

uniQure Prices Upsized $225M Public Offering at Discount to Market

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$49.24
Mkt Cap
$3.055B
52W Low
$8.73
52W High
$71.5
52W Position info
464% above low
Off High info
31% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

QURE has more than doubled off its 52-week low of $8.73 on elevated volume (2.2× avg).

Summary

uniQure priced an upsized $225 million public offering of ordinary shares at $45.50 per share, a discount to its recent market price, to fund commercialization and development activities.


Key Events · Financing and Capital Events · QURE

  • Offering Priced and Upsized

    uniQure priced an upsized public offering of 4,945,055 ordinary shares at $45.50 per share, raising approximately $225 million in gross proceeds. This finalizes the terms of the offering initially announced on June 22, 2026.

  • Discounted Pricing

    The offering price of $45.50 per share represents a discount compared to the last reported sale price of $49.04 on June 23, 2026.

  • Significant Dilution

    The offering represents a substantial capital raise relative to the company's market capitalization, with potential for further dilution if underwriters exercise their option to purchase an additional 741,758 shares.

  • Strategic Use of Proceeds

    Net proceeds of approximately $211.5 million are intended to fund commercialization readiness for AMT-130, its confirmatory study, development of other clinical candidates, and general corporate purposes.


Analysis · QURE · Life Sciences

uniQure has finalized the terms of its public offering, upsizing it to $225 million. The offering is priced at a discount to the last reported sale price, indicating a significant capital raise that will be dilutive to existing shareholders. The proceeds are earmarked for critical activities including commercialization readiness for AMT-130, funding its confirmatory study, and advancing other clinical candidates, which are essential following recent positive regulatory developments for AMT-130.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, QURE was trading at $49.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $8.73 to $71.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

QURE - Latest Insights

QURE
Nov 04, 2026, 7:28 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $22.60
Real-time Price: $23.81 info
Change: +$1.21 (+5%) info
Market Cap: $1.67B info
QURE
Nov 04, 2026, 7:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.44
Real-time Price: $23.81 info
Change: +$1.37 (+6%) info
Market Cap: $1.67B info
QURE
Nov 02, 2026, 7:05 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $27.66
Real-time Price: $23.81 info
Change: -$3.85 (-14%) info
Market Cap: $1.67B info
QURE
Sep 29, 2026, 9:26 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $22.00
Real-time Price: $23.81 info
Change: +$1.81 (+8%) info
Market Cap: $1.67B info
QURE
Sep 29, 2026, 9:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $22.20
Real-time Price: $23.81 info
Change: +$1.61 (+7%) info
Market Cap: $1.67B info